🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Novo Nordisk weight loss rollout to prompt ‘dramatic upgrades’ - analysts

Published 13/05/2024, 13:41
© Reuters Novo Nordisk weight loss rollout to prompt ‘dramatic upgrades’ - analysts
NOVOb
-

Proactive Investors - Novo Nordisk (CSE:NOVOb) could be in line for ‘dramatic earnings upgrades’ as pace builds on the rollout of its weight loss drugs, analysts say.

Wegovy sales could hit 76 billion Danish Krone (US$11 billion) this year, Morgan Stanley (NYSE:MS) said in a note, after starter doses increased six-fold up to early May.

This would see sales of the GLP-1-based weight loss drug, which mimics hormones that lower blood sugar and suppress hunger, sit 23% ahead of Novo’s compiled consensus.

“The acceleration in Wegovy starting dose prescriptions, if sustained, could support dramatic earnings upgrades,” Morgan Stanley said as a result.

Based on US trends, the figure could theoretically hit 127 billion Danish Krone, seeing Morgan Stanley’s revenue growth forecast increased to over 50%, against current market consensus of 25%.

An ‘overweight’ rating was offered as a result, alongside a 990 Danish Krone share price target, up on Friday’s close of 883.2.

“We continue to believe that Novo and Lilly are set to dominate the diabesity market, retaining their duopoly for the foreseeable future,” the bank said.

Citi analysts highlighted a ‘buy’ rating for the drug firm in the meantime, noting Wegovy starter doses were “rocketing”.

Tight supply chains could cap this though, Citi said, with a 975 Danish Krone share price target being offered.

Morgan Stanley pointed to significant investment by Novo in such supply chains, adding this created barriers to entry for rivals.

“Whilst significant uncertainty continues to exist when it comes to supply dynamics, our modelling suggests that total Wegovy weekly prescriptions could reach 330,000 by the end of June,” the bank said, against roughly 25,000 over the first quarter.

Read more on Proactive Investors UK

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.